Whole-Body Blood Test Platform

About Curve Biosciences

Curve Biosciences is pioneering a novel diagnostic paradigm it calls 'Whole-Body Intelligence,' which leverages a foundational atlas of over 400,000 manually curated tissue samples to train AI models for blood-based organ health monitoring. The company's core thesis is that existing liquid biopsy tests are limited by models trained on 'opaque, chaotic blood data,' and that grounding detection algorithms in verified tissue biology will yield superior clinical accuracy. Its initial focus is on resolving chronic diseases through earlier, more precise detection of organ dysfunction, targeting a massive market need driven by rising chronic disease prevalence and healthcare costs. The leadership team combines deep expertise from top-tier diagnostic companies like GRAIL, Natera, and Genentech, alongside academic innovation from Stanford.

Therapeutic Areas